

Monday, April 18, 2005

COMPANY PRESS RELEASE

AACR Sessions Highlight Contributions of Transgenomic Technology to Cancer Research

Enabling Analysis of Genomic Biomarkers in Translational & Clinical Research

Anaheim, Calif., April 18 / -- Transgenomic Inc. ([Nasdaq: TBIO](#)) announced today that during the American Association of Cancer Research annual meeting currently underway in Anaheim, a number of its customers from major research institutions and pharmaceutical companies worldwide will present results in which the Company's products and/or services have played an important role. Specific scientific applications represented among these presentations include: (i) mutational analysis of important drug targets and related genes; (ii) analysis of the methylation status and/or polymorphisms in genes encoding key drug-metabolizing enzymes; (iii) detection of cancer-associated mutations in DNA isolated from blood serum or plasma; (iv) analysis of genetic variation associated with cancer predisposition; and (v) development of new analytical techniques.

Stan Lilleberg, Ph.D., Transgenomic's Director of Translational and Clinical Research, commented that "Increased understanding of the molecular genetics of cancer has led to the discovery of a variety of novel targets for cancer therapy, as well as new ideas for early detection of disease, tailoring individual therapeutic intervention strategies, and monitoring the progress of therapy or emergence of drug resistance at the molecular level." Lilleberg continued, "The incorporation of genomic biomarker analyses into translational and clinical research protocols is a critical component for the continued advancement of such concepts. We are presenting data at this meeting that has resulted from the efforts of our Discovery Services unit to enable highly sensitive mutational analysis of key signal transduction pathways in clinical specimens."

Transgenomic CEO, Collin D'Silva, stated "In a number of settings, Transgenomic's WAVE[®] System has proven to be a uniquely enabling technology for detection of low-abundance somatic mutations in a variety of clinical specimens, a critical component of the transition from 'bench to bedside' in cancer research." D'Silva continued, "This versatile instrument platform, together with our SURVEYOR[™] mutation detection kits, related consumable products, and the unique capabilities of our Discovery Services unit, allows us to offer a comprehensive set of solutions to the cancer research community." He concluded, "Our products and services are meeting an expanding need for genomic biomarker analysis to support the development of novel diagnostic and therapeutic strategies."

About Transgenomic

Transgenomic provides versatile and innovative research tools and related consumable products. Transgenomic's biosystems segment offers its WAVE Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. These systems have broad applicability to genetic research and molecular diagnostics. To date there have been approximately one thousand systems installed in over 30 countries around the world. In addition, the BioSystems segment offers WAVE-based biomarker discovery and validation services in support of translational research, pre-clinical and clinical studies. Through its nucleic acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents used in the manufacture of synthetic oligonucleotides. For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's Web site at www.transgenomic.com.

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any

future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Corporation's products and services to meet an expanding need for genomic biomarker analysis in support of the development of novel diagnostic and therapeutic strategies. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For confirmation of release or further information, please contact:

Mitchell L. Murphy
Transgenomic Inc.
402-452-5418
mmurphy@transgenomic.com

Robert J. Pogulis, Ph.D.
Transgenomic Inc.
845-782-9617
rpogulis@transgenomic.com